Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review
- PMID: 28294322
- DOI: 10.1002/jcp.25911
Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review
Abstract
Altered gut bacteria and bacterial metabolic pathways are two important factors in initiation and progression of inflammatory bowel disease (IBD). However, efficacy of probiotics in remission of patients with IBD has not been characterized. This study was performed on the studies that specifically assessed the efficacy of probiotics in attaining clinical response on patients with various types of IBD. The efficacy of variant species of probiotics in different conditions and the influence of study quality in outcomes of randomized controlled trials (RCTs) were also assessed. The RCTs were collected by searching in MEDLINE Web of Science and Google scholar. Then all studies were abstracted in abstraction form and the outcomes were analyzed with fixed-effect and mixed-effect models for assessment of efficacy of variant species of probiotics in subgroups of IBDs. Analysis of 9 trials showed that probiotics had not significant effect on Crohn's disease (CD) (p = 0.07) but analysis of 3 trials in children with IBD revealed a significant advantage (p < 0.01). Analysis of 18 trials revealed that probiotics in patients with Ulcerative colitis (UC) in different conditions have significant effects (p = 0.007). VSL#3 probiotics in patients with UC had significant effect (p < 0.01). Combination of Lactobacillus probiotic, prebiotics had significant effect (p = 0.03) only in patients with UC. Combination of Saccharomyces boulardii, Lactobacillus, and VSL#3 probiotics in CD had also a trend for efficiency (p = 0.057). In children with IBD, the combination of Lactobacillus with VSL#3 probiotics had significant effect (p < 0.01). Probiotics are beneficial in IBD, especially the combination ones in UC.
Keywords: Crohn's disease; IBD; probiotics; ulcerative colitis.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
Gut microbiome-targeted therapies as adjuvant treatments in inflammatory bowel diseases: a systematic review and network meta-analysis.J Gastroenterol Hepatol. 2025 Jan;40(1):78-88. doi: 10.1111/jgh.16795. Epub 2024 Oct 31. J Gastroenterol Hepatol. 2025. PMID: 39482823
-
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2. Cochrane Database Syst Rev. 2021. PMID: 34844288 Free PMC article.
-
Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.Drugs. 2012 Apr 16;72(6):803-23. doi: 10.2165/11632710-000000000-00000. Drugs. 2012. PMID: 22512365
-
Probiotics for maintenance of remission in Crohn's disease.Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004826. doi: 10.1002/14651858.CD004826.pub2. Cochrane Database Syst Rev. 2006. PMID: 17054217
-
Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.Aliment Pharmacol Ther. 2017 Aug;46(4):389-400. doi: 10.1111/apt.14203. Epub 2017 Jun 27. Aliment Pharmacol Ther. 2017. PMID: 28653751
Cited by
-
Importance of Gut Microbiota in Patients with Inflammatory Bowel Disease.Nutrients. 2024 Jun 30;16(13):2092. doi: 10.3390/nu16132092. Nutrients. 2024. PMID: 38999840 Free PMC article. Review.
-
Gut microbiota analysis for prediction of clinical relapse in Crohn's disease.Sci Rep. 2022 Nov 19;12(1):19929. doi: 10.1038/s41598-022-23757-x. Sci Rep. 2022. PMID: 36402792 Free PMC article.
-
Human Breast Milk Promotes the Secretion of Potentially Beneficial Metabolites by Probiotic Lactobacillus reuteri DSM 17938.Nutrients. 2019 Jul 9;11(7):1548. doi: 10.3390/nu11071548. Nutrients. 2019. PMID: 31323989 Free PMC article.
-
Immune System Dysregulation During Spaceflight: Potential Countermeasures for Deep Space Exploration Missions.Front Immunol. 2018 Jun 28;9:1437. doi: 10.3389/fimmu.2018.01437. eCollection 2018. Front Immunol. 2018. PMID: 30018614 Free PMC article. Review.
-
The administration of Enterococcus faecium SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice.Front Microbiol. 2022 Dec 16;13:1054097. doi: 10.3389/fmicb.2022.1054097. eCollection 2022. Front Microbiol. 2022. PMID: 36590404 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical